Clinical Perspectives 8 (open)
Integrating Behavioral and Medical Findings from Studies Assessing Risk, Efficacy, Tolerability, and Safety for Children Receiving Antipsychotic Medications

Tuesday, October 22, 2013: 1:00 PM-4:00 PM
Chair:
Saundra Stock, MD
 
8.1
Efficacy and Tolerability of Antipsychotics in Youth with Severe Psychiatric Disorders: Results from Randomized Controlled Trials
Christoph U. Correll, MD Hofstra North Shore LIJ School of Medicine, Glen Oaks, NY
 
8.2
Rationale for the Implementation of Prior Authorization for Children Under Six Years Old Who are the Target of Proposed Antipsychotic Treatment
Robert J. Constantine, PhD University of South Florida, Tampa, FL
Michael Bengtson, MD University of South Florida, Tampa, FL
 
8.3
Pharmacoepidemiological Studies of Second-Generation Antipsychotics and Risk of Type 2 Diabetes
Tobias Gerhard, PhD Rutgers University, New Brunswick, NJ
William V. Bobo, MD, MPH Mayo Clinic, Rochester, MN
Mark Olfson, MD, MPH Columbia University, New York, NY
Stephen Crystal, PhD Rutgers University, Princeton, NJ
 
8.4
The Design and Early Implementation of a Prior Authorization Process for the Use of Antipsychotics Among Children Under Six Years Old
Saundra Stock, MD Morsani College of Medicine at the University of South Florida, Tampa, FL

See more of: Clinical Perspectives
Copyright ©2013 - American Academy of Child Adolescent Psychiatry. All Rights Reserved.